The optic neuritis treatment trial : A definitive answer and profound impact with unexpected results

Archives of Ophthalmology

Volumn 126, Issue 7, 2008, Pages 996-999

  Volpe, Nicholas J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE;

ARTICLE; CONTACT SENSITIVITY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

ADMINISTRATION, ORAL; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRAVENOUS; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PREDNISONE; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 47549107625     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.126.7.996     Document Type: Article

References (52)

1. Buzzard T. Atrophy of the optic nerve as a symptom of chronic disease of the central nervous system. BMJ. 1893;2:779-784.
2. Nettleship E. On cases of retro-ocular neuritis. Trans Ophthalmol Soc U K. 1884;4:186-226.
3. von Graefe A. Ueber complication von sehnervenentzundung mit gehirnkrankheiten. Arch Ophtalmol (Paris). 1860;1:58-71.
4. Rizzo JF III, Lessell S. Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study. Neurology. 1988;38(2):185-190.
5. Beck RW. The Optic Neuritis Treatment Trial. Arch Ophthalmol. 1988;106(8):1051-1053.
6. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis: The Optic Neuritis Study Group. N Engl J Med. 1992;326(9):581-588.
7. The clinical profile of optic neuritis: experience of the Optic Neuritis Treatment Trial: Optic Neuritis Study Group. Arch Ophthalmol. 1991;109(12):1673-1678.
8. Wang JC, Tow S, Aung T, Lim SA, Cullen JF. The presentation, aetiology, management and outcome of optic neuritis in an Asian population. Clin Experiment Ophthalmol. 2001;29(5):312-315.
9. Phillips PH, Newman NJ, Lynn MJ. Optic neuritis in African Americans. Arch Neurol. 1998;55(2):186-192.
10. Beck RW. Comparison of the ONTT intravenous group and the CHAMPS placebo group. J Neuroophthalmol. 2001;21(4):310.
11. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis: CHAMPS Study Group. N Engl J Med. 2000;343(13):898-904.
12. Kapoor R, Miller DH, Jones SJ, et al. Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology. 1998;50(1):230-237.
13. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology. 1999;52(7):1479-1484.
14. Trauzettel-Klosinski S, Aulhorn E, Diener HC, Minder C, Pfluger D. The Tübingen Study on Optic Neuritis Treatment: a prospective randomized and controlled trial. Clin Vis Sci. 1993;8:385-394.
15. Wakakura M, Mashimo K, Oono S, et al. Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan: Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Jpn J Ophthalmol. 1999;43(2):133-138.
16. Rawson MD, Liversedge LA. Treatment of retrobulbar neuritis with corticotrophin. Lancet. 1969;2(7613):222.
17. Rawson MD, Liversedge LA, Goldfarb G. Treatment of acute retrobulbar neuritis with corticotrophin. Lancet. 1966;2(7472):1044-1046.
18. Bowden AN, Bowden PM, Friedmann AI, Perkin GD, Rose FC. A trial of cortico-trophin gelatin injection in acute optic neuritis. J Neurol Neurosurg Psychiatry. 1974;37(8):869-873.
19. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol. 2000;247(6):435-442.
20. Kaufman DI, Trobe JD, Eggenberger ER, Whitaker JN. Practice parameter, the role of corticosteroids in the management of acute monosymptomatic optic neuritis: report of the Quality Standards Subcommittee of The American Academy of Neurology(1). Am J Ophthalmol. 2000;130(4):541.
21. Vedula SS, Brodney-Folse S, Gal RL, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev. 2007;(1):CD001430.
22. Beck RW. The optic neuritis treatment trial: implications for clinical practice: Optic Neuritis Study Group. Arch Ophthalmol. 1992;110(3):331-332.
23. Ghosh A, Kelly SP, Mathews J, Cooper PN, Macdermott N. Evaluation of the management of optic neuritis: audit on the neurological and ophthalmological practice in the north west of England. J Neurol Neurosurg Psychiatry. 2002;72(1):119-121.
24. Trobe JD, Sieving PC, Guire KE, Fendrick AM. The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists. Ophthalmology. 1999;106(11):2047-2053.
25. Goodin DS. Treatment of optic neuritis. Neurology. 1993;43(12):2731-2732.
26. Goodin DS. Corticosteroids and optic neuritis. Neurology. 1993;43(3, pt 1):632-634.
27. Goodin DS. Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology. 1999;18(2):53-63.
28. Beck RW, Cleary PA. Optic neuritis treatment trial: one-year follow-up results. Arch Ophthalmol. 1993;111(6):773-775.
29. Kupersmith MJ, Gal RL, Beck RW, Xing D, Miller N. Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome. Neurology. 2007;69(6):508-514.
30. Chrousos GA, Kattah JC, Beck RW, Cleary PA. Side effects of glucocorticoid treatment: experience of the Optic Neuritis Treatment Trial. JAMA. 1993;269(16):2110-2112.
31. Kupersmith MJ, Kaufman D, Paty DW, et al. Megadose corticosteroids in multiple sclerosis. Neurology. 1994;44(1):1-4.
32. Trobe JD, Beck RW, Moke PS, Cleary PA. Contrast sensitivity and other vision tests in the optic neuritis treatment trial. Am J Ophthalmol. 1996;121(5):547-553.
33. Katz B. The dyschromatopsia of optic neuritis: a descriptive analysis of data from the optic neuritis treatment trial. Trans Am Ophthalmol Soc. 1995;93:685-708.
34. Keltner JL, Johnson CA, Spurr JO, Beck RW. Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial: Optic Neuritis Study Group. Arch Ophthalmol. 1993;111(2):231-234.
35. Pollock SC. Visual fields in optic neuritis. Arch Ophthalmol. 1993;111(10):1315-1317.
36. Arnold AC. Visual field defects in the optic neuritis treatment trial: central vs peripheral, focal vs global. Am J Ophthalmol. 1999;128(5):632-634.
37. Fang JP, Donahue SP, Lin RH. Global visual field involvement in acute unilateral optic neuritis. Am J Ophthalmol. 1999;128(5):554-565.
38. Keltner JL, Johnson CA, Spurr JO, Beck RW. Comparison of central and peripheral visual field properties in the optic neuritis treatment trial. Am J Ophthalmol. 1999;128(5):543-553.
39. Beck RW, Kupersmith MJ, Cleary PA, Katz B. Fellow eye abnormalities in acute unilateral optic neuritis: experience of the optic neuritis treatment trial. Ophthalmology. 1993;100(5):691-698.
40. Keltner JL, Johnson CA, Spurr JO, Beck RW. Visual field profile of optic neuritis: one-year follow-up in the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1994;112(7):946-953.
41. Beck RW, Cleary PA, Backlund JC. The course of visual recovery after optic neuritis: experience of the Optic Neuritis Treatment Trial. Ophthalmology. 1994;101(11):1771-1778.
42. Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial: The Optic Neuritis Study Group. Arch Ophthalmol. 1997;115(12):1545-1552.
43. Cleary PA, Beck RW, Bourque LB, Backlund JC, Miskala PH. Visual symptoms after optic neuritis: results from the Optic Neuritis Treatment Trial. J Neuroophthalmol. 1997;17(1):18-28.
44. Cole SR, Beck RW, Moke PS, Gal RL, Long DT. The National Eye Institute Visual Function Questionnaire: experience of the ONTT, Optic Neuritis Treatment Trial. Invest Ophthalmol Vis Sci. 2000;41(5):1017-1021.
45. Beck RW, Smith CH, Gal RL, et al. Neurologic impairment 10 years after optic neuritis. Arch Neurol. 2004;61(9):1386-1389.
46. Kaufman DI; The Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow up. Paper presented at: the American Academy of Ophthalmology; November 12, 2007; New Orleans, LA.
47. The 5-year risk of MS after optic neuritis: experience of the Optic Neuritis Treatment Trial: Optic Neuritis Study Group. Neurology. 1997;49(5):1404-1413.
48. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis: The Optic Neuritis Study Group. N Engl J Med. 1993;329(24):1764-1769.
49. Beck RW, Trobe JD. The Optic Neuritis Treatment Trial: putting the results in perspective, The Optic Neuritis Study Group. J Neuroophthalmol. 1995;15(3):131-135.
50. Silberberg DH. Corticosteroids and optic neuritis. N Engl J Med. 1993;329(24):1808-1810.
51. Hickman SJ, Dalton CM, Miller DH, Plant GT. Management of acute optic neuritis. Lancet. 2002;360(9349):1953-1962.
52. Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003;121(7):944-949.